US7097839B1
(en)
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US6898532B1
(en)
|
1995-06-07 |
2005-05-24 |
Biomerieux, Inc. |
Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
|
US6429017B1
(en)
|
1999-02-04 |
2002-08-06 |
Biomerieux |
Method for predicting the presence of haemostatic dysfunction in a patient sample
|
US6321164B1
(en)
|
1995-06-07 |
2001-11-20 |
Akzo Nobel N.V. |
Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
|
US7030152B1
(en)
|
1997-04-02 |
2006-04-18 |
The Brigham And Women's Hospital, Inc. |
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
|
US6727102B1
(en)
*
|
1997-06-20 |
2004-04-27 |
Leuven Research & Development Vzw |
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
|
US6502040B2
(en)
|
1997-12-31 |
2002-12-31 |
Biomerieux, Inc. |
Method for presenting thrombosis and hemostasis assay data
|
ATE253223T1
(en)
*
|
1998-08-27 |
2003-11-15 |
Mayo Foundation |
METHODS AND MATERIALS FOR DIAGNOSING UNSTABLE ANGINA
|
US6309888B1
(en)
*
|
1998-09-04 |
2001-10-30 |
Leuven Research & Development Vzw |
Detection and determination of the stages of coronary artery disease
|
JP4486260B2
(en)
*
|
1999-02-04 |
2010-06-23 |
バイオメリュー・インコーポレイテッド |
Method and apparatus for predicting the presence of hemostatic dysfunction in patient samples
|
EP1767223A1
(en)
*
|
1999-08-31 |
2007-03-28 |
The Brigham And Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
AU782386C
(en)
*
|
1999-08-31 |
2006-08-10 |
Brigham And Women's Hospital |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
EP1520590A1
(en)
*
|
1999-08-31 |
2005-04-06 |
The Brigham and Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
GB9929140D0
(en)
*
|
1999-12-10 |
2000-02-02 |
Univ Geneve |
Diagnostic assay for stroke
|
US7179612B2
(en)
*
|
2000-06-09 |
2007-02-20 |
Biomerieux, Inc. |
Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
WO2002038794A2
(en)
|
2000-11-09 |
2002-05-16 |
The Brigham And Women's Hospital, Inc. |
Cardiovascular disease diagnostic and therapeutic targets
|
EP1386165B1
(en)
*
|
2000-12-14 |
2011-11-02 |
The Brigham And Women's Hospital, Inc. |
Inflammatory markers for detection and prevention of diabetes mellitus
|
US6855509B2
(en)
*
|
2000-12-19 |
2005-02-15 |
Instrumentation Laboratory Company |
Protein S functional assay and kit therefor
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
BR0206273A
(en)
|
2001-01-02 |
2006-11-21 |
Cleveland Clinic Foundation |
diagnostic tests to characterize a human patient's risk of developing or presenting cardiovascular disease and to evaluate a therapeutic agent for cardiovascular disease in a subject suspected of presenting or presenting cardiovascular disease;
|
US6500630B2
(en)
|
2001-01-12 |
2002-12-31 |
Mayo Foundation For Medical Education And Research |
Marker for inflammatory conditions
|
NZ525921A
(en)
*
|
2001-01-26 |
2005-06-24 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
EP1401456A4
(en)
*
|
2001-02-21 |
2005-04-20 |
Merck & Co Inc |
Method fron determining the efficacy of reverse cholesterol transport enhancing agents
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
US7713705B2
(en)
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US7608406B2
(en)
|
2001-08-20 |
2009-10-27 |
Biosite, Inc. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
CA2460340C
(en)
*
|
2001-09-21 |
2011-02-15 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
WO2003040691A2
(en)
|
2001-11-05 |
2003-05-15 |
The Brigham And Women's Hospital, Inc. |
Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
|
DE60232910D1
(en)
*
|
2001-11-09 |
2009-08-20 |
Medstar Res Inst |
METHOD FOR THE USE OF PHYSIOLOGICAL MARKERS FOR THE EVALUATION OF A HEART CIRCUIT RISK
|
AU2002352726A1
(en)
|
2001-11-15 |
2003-06-10 |
Galileo Laboratories, Inc. |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040071633A1
(en)
*
|
2002-02-19 |
2004-04-15 |
Wright Samuel D. |
Method for determining efficacy of reverse cholesterol transport enhancing agents
|
ES2685697T3
(en)
|
2002-05-09 |
2018-10-10 |
The Brigham And Women's Hospital, Inc. |
1L1RL-1 as a marker of cardiovascular diseases
|
US20050049248A1
(en)
*
|
2002-07-29 |
2005-03-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
|
US7763649B2
(en)
*
|
2002-07-29 |
2010-07-27 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for controlling connexin 43 expression
|
US20050059635A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
|
US7320997B2
(en)
*
|
2002-07-29 |
2008-01-22 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
|
US20050009788A1
(en)
*
|
2002-07-29 |
2005-01-13 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling connexin 43 expression
|
BRPI0313155B8
(en)
*
|
2002-07-29 |
2021-05-25 |
Cardax Pharmaceuticals Inc |
chemical compound derived or carotenoid analogue, pharmaceutical composition, and use of the compound
|
US20050004235A1
(en)
*
|
2002-07-29 |
2005-01-06 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050026874A1
(en)
*
|
2002-07-29 |
2005-02-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
|
US7345091B2
(en)
*
|
2002-07-29 |
2008-03-18 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
US20050059659A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for controlling C-reactive protein levels
|
US7521584B2
(en)
*
|
2002-07-29 |
2009-04-21 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of disease
|
US7375133B2
(en)
*
|
2002-07-29 |
2008-05-20 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
US7723327B2
(en)
*
|
2002-07-29 |
2010-05-25 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050143475A1
(en)
*
|
2002-07-29 |
2005-06-30 |
Lockwood Samuel F. |
Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
|
US20050148517A1
(en)
*
|
2002-07-29 |
2005-07-07 |
Lockwood Samuel F. |
Carotenoid ether analogs or derivatives for controlling connexin 43 expression
|
EP1551382A4
(en)
|
2002-09-27 |
2007-01-24 |
Martek Biosciences Corp |
Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
|
US7851486B2
(en)
*
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US7507531B2
(en)
*
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
AU2003291012A1
(en)
*
|
2002-11-15 |
2004-06-15 |
Galileo Pharmaceuticals, Inc. |
Chroman derivatives for the reduction of inflammation symptoms
|
AU2003297916A1
(en)
*
|
2002-12-12 |
2004-07-09 |
Activbiotics, Inc. |
Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
|
US20050026168A1
(en)
*
|
2002-12-13 |
2005-02-03 |
Genesis Group Inc. |
Method for the detection of risk factors associated with myocardial infarction
|
GB0229747D0
(en)
*
|
2002-12-20 |
2003-01-29 |
Axis Shield Asa |
Assay
|
DE602004018617D1
(en)
*
|
2003-03-07 |
2009-02-05 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
|
ATE406364T1
(en)
*
|
2003-03-07 |
2008-09-15 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US20040180868A1
(en)
*
|
2003-03-12 |
2004-09-16 |
Mullally John P. |
Composition and method for treating inflammations by reducing C-reactive protein
|
US20040192660A1
(en)
*
|
2003-03-12 |
2004-09-30 |
Mullally John P. |
Protocol for improving vision
|
US20050026979A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Maha Ghazzi |
Methods for treating inflammation and inflammation-associated diseases with a statin and ether
|
US20050272051A1
(en)
*
|
2003-09-17 |
2005-12-08 |
Decode Genetics Ehf. |
Methods of preventing or treating recurrence of myocardial infarction
|
EP1673465A4
(en)
*
|
2003-09-29 |
2008-04-30 |
Biosite Inc |
Methods and compositions for the diagnosis of sepsis
|
US20080085329A1
(en)
*
|
2003-10-22 |
2008-04-10 |
Fred Hutchinson Cancer Research Center, Inc. |
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
|
WO2005046675A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Jordan Holtzman |
Methods for enhancing glutathione peroxidase activity
|
EP1694342B1
(en)
*
|
2003-11-12 |
2020-11-04 |
Trustees Of The University Of Pennsylvania |
Methods of using gelsolin to treat or prevent bacterial sepsis
|
US9408891B2
(en)
*
|
2003-11-12 |
2016-08-09 |
The Trustees Of The University Of Pennsylvania |
Methods of using gelsolin to treat or prevent bacterial sepsis
|
US7781219B2
(en)
|
2003-12-05 |
2010-08-24 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
US20080279843A1
(en)
*
|
2003-12-09 |
2008-11-13 |
Essential Skincare, Llc |
Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20050181451A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Bates Harold M. |
Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
|
US20050250745A1
(en)
*
|
2004-02-25 |
2005-11-10 |
Seddon Johanna M |
Biomarkers for age-related macular degeneration (AMD)
|
US20060058269A1
(en)
*
|
2004-04-14 |
2006-03-16 |
Lockwood Samuel F |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
CA2564066A1
(en)
*
|
2004-04-14 |
2005-11-03 |
Hawaii Biotech, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
ES2464444T3
(en)
*
|
2004-05-12 |
2014-06-02 |
The Brigham And Women's Hospital, Inc. |
Gelsolin for use in the treatment of infections
|
CA2567223A1
(en)
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
ES2571929T3
(en)
*
|
2004-05-26 |
2016-05-27 |
Region Nordjylland |
Procedure to determine the amount of circulating CD36
|
US8335652B2
(en)
|
2004-06-23 |
2012-12-18 |
Yougene Corp. |
Self-improving identification method
|
US8027791B2
(en)
|
2004-06-23 |
2011-09-27 |
Medtronic, Inc. |
Self-improving classification system
|
US20060020043A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Methods and compositions for reducing C-reactive protein
|
WO2006020498A2
(en)
|
2004-08-11 |
2006-02-23 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
WO2006031592A1
(en)
*
|
2004-09-09 |
2006-03-23 |
University Of Massachusetts |
Disease markers for early stage atherosclerosis
|
US20060088860A1
(en)
*
|
2004-09-13 |
2006-04-27 |
Lipomics Technologies, Inc. |
Metabolite markers for weight management
|
EP1809759B1
(en)
*
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
BRPI0517148A
(en)
*
|
2004-12-06 |
2008-09-30 |
Univ California |
method for improving the structure and / or function of arterioles; active agent and treatment kit
|
PT1879599E
(en)
*
|
2005-04-20 |
2014-01-23 |
Hutchinson Fred Cancer Res |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
KR20080007491A
(en)
*
|
2005-04-29 |
2008-01-21 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US20070099239A1
(en)
*
|
2005-06-24 |
2007-05-03 |
Raymond Tabibiazar |
Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
|
WO2007094200A1
(en)
*
|
2006-02-14 |
2007-08-23 |
Pola Chemical Industries Inc. |
Skin-whitening cosmetic
|
PL2001496T3
(en)
|
2006-03-15 |
2017-10-31 |
Brigham & Womens Hospital Inc |
Use of gelsolin to diagnose and treat inflammatory diseases
|
PT2002258T
(en)
*
|
2006-03-15 |
2017-12-18 |
The Brigham And Women`S Hospital Inc |
Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
|
ATE476657T1
(en)
|
2006-04-24 |
2010-08-15 |
Critical Care Diagnostics Inc |
PREDICTION OF LETHALITY AND DETECTION OF SERIOUS DISEASES
|
US20090305265A1
(en)
*
|
2006-04-27 |
2009-12-10 |
Critical Care Diagnostics, Inc. |
Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
|
HUE028594T2
(en)
*
|
2006-05-01 |
2016-12-28 |
Critical Care Diagnostics Inc |
Diagnosis of cardiovascular disease
|
PL2019965T3
(en)
*
|
2006-05-02 |
2015-10-30 |
Critical Care Diagnostics Inc |
Differential diagnosis between pulmonary and cardiovascular disease
|
EP2030025A2
(en)
*
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
CN101627135B
(en)
*
|
2007-02-05 |
2013-04-10 |
北日德兰大区 |
A method for diagnosing atherosclerotic plaques by measurement of CD36
|
US9422363B2
(en)
|
2007-08-28 |
2016-08-23 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009032722A1
(en)
*
|
2007-08-29 |
2009-03-12 |
The Cleveland Clinic Foundation |
Carbamylated proteins and risk of cardiovascular disease
|
EP3070477B1
(en)
|
2007-12-05 |
2019-02-20 |
The Cleveland Clinic Foundation |
Trimethylamine compounds as risk predictors of cardiovascular disease
|
EP2708603B1
(en)
|
2008-01-25 |
2017-04-19 |
The General Hospital Corporation |
Diagnostic and therapeutic uses of gelsolin in renal failure
|
ES2687401T3
(en)
|
2008-04-18 |
2018-10-25 |
Critical Care Diagnostics, Inc. |
Prediction of the risk of serious adverse cardiac events
|
CN103251631A
(en)
*
|
2008-05-13 |
2013-08-21 |
根梅迪卡治疗公司 |
Salicylate conjugates useful for treating metabolic disorders
|
US20100105746A1
(en)
*
|
2008-08-01 |
2010-04-29 |
Clary Clish |
Method for treating metabolic diseases
|
US10241093B2
(en)
|
2009-05-28 |
2019-03-26 |
The Cleveland Clinic Foundation |
Trimethylamine-containing compounds for diagnosis and prediction of disease
|
US11835503B2
(en)
|
2009-05-28 |
2023-12-05 |
The Cleveland Clinic Foundation |
TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
|
JP5379616B2
(en)
|
2009-09-09 |
2013-12-25 |
株式会社日立製作所 |
Marker factors and applications of atherosclerosis
|
WO2011060361A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Bg Medicine, Inc. |
Risk factors and prediction of myocardial infarction
|
JP6215713B2
(en)
|
2011-03-17 |
2017-10-18 |
クリティカル ケア ダイアグノスティクス インコーポレイテッド |
How to predict the risk of adverse clinical outcomes
|
US8708906B1
(en)
*
|
2011-09-07 |
2014-04-29 |
Allen J. Orehek |
Method for the prevention of dementia and Alzheimer's disease
|
JP6450679B2
(en)
|
2012-08-21 |
2019-01-09 |
クリティカル ケア ダイアグノスティクス インコーポレイテッド |
Multi-marker risk stratification
|
KR102367981B1
(en)
*
|
2012-12-12 |
2022-02-25 |
메소블라스트, 아이엔씨. |
Treatment of diseases of endothelial dysfunction and inflammation
|
US20150315644A1
(en)
|
2014-05-05 |
2015-11-05 |
Medtronic, Inc. |
Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection
|
MX2017001432A
(en)
|
2014-07-31 |
2017-05-09 |
Uab Res Found |
Apoe mimetic peptides and higher potency to clear plasma cholesterol.
|
US10328045B2
(en)
|
2014-09-12 |
2019-06-25 |
Children's Medical Center Corporation, Inc. |
Dietary emulsion formulations and methods for using the same
|
FI127416B
(en)
*
|
2016-09-29 |
2018-05-31 |
Oy Medix Biochemica Ab |
Method for determining risks associated with cardiovascular diseases
|